Males and females with type 2 diabetes (receiving pharmacologic treatment for at least 6 months or longer) with stable diabetes therapy

Lipid-lowering therapy must be unchanged for at least 4 weeks or more

Subjects receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 100 mg/dL

Subjects not receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 130 mg/dL

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia